A Pharmacovigilance Study of Immune Checkpoint Inhibitor-Associated Cholangitis: Insights From the FDA Adverse Event Reporting System.

Tan H, Ou X, Chen Y, Lan W, Luo L.

DOI: 10.1111/hepr.70082
Published: 2025-11-24
Container: Hepatol Res
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/hepr.70082,
  title = {A Pharmacovigilance Study of Immune Checkpoint Inhibitor-Associated Cholangitis: Insights From the FDA Adverse Event Reporting System.},
  author = {Tan H and  Ou X and  Chen Y and  Lan W and  Luo L.},
  year = {2026},
  journal = {Hepatol Res},
  doi = {10.1111/hepr.70082},
  url = {https://doi.org/10.1111/hepr.70082}
}

RIS

TY  - JOUR
TI  - A Pharmacovigilance Study of Immune Checkpoint Inhibitor-Associated Cholangitis: Insights From the FDA Adverse Event Reporting System.
AU  - Tan H
AU  -  Ou X
AU  -  Chen Y
AU  -  Lan W
AU  -  Luo L.
PY  - 2026
JO  - Hepatol Res
DO  - 10.1111/hepr.70082
UR  - https://doi.org/10.1111/hepr.70082
ER  -

APA

H, T., X, O., Y, C., W, L., & L., L. (2026). A Pharmacovigilance Study of Immune Checkpoint Inhibitor-Associated Cholangitis: Insights From the FDA Adverse Event Reporting System.. Hepatol Res. https://doi.org/10.1111/hepr.70082

Source records

europe-pmc · retrieved 2026-09-27T08:28:35.690Z